Estrogen Receptor-positive Breast Cancer — The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer
Citation(s)
The Value of 18F-FES-PET/CT in Predicting the Efficacy of Fulvestrant as First-line Treatment in Postmenopausal Patients With Hormone Receptor-positive Advanced Breast Cancer - a Multicenter Prospective Study